Explore the potential benefits, risks, and side effects associated with stem cell therapy for leukemia. Dr. David Greene in Arizona offers an array of hope via stem cell therapy for Leukemia patients.

Stem Cell Therapy for Leukemia: A Promising Cure | Dr. David Greene Arizona

Synopsis: 
Dr. Paul Bolno is the President and CEO of Wave Life Sciences, a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases including Duchenne muscular dystrophy and Alpha-1 antitrypsin deficiency. Paul discusses his early years at GSK and the events that led him to join Wave as CEO, and some of his early learnings during that transition from big pharma to a biotech. He also talks about the role and opportunity that RNA presents in medicine, where he sees RNA therapeutics going next, and what excites him about the emerging field of RNA editing.

Biography: 
Dr. Bolno has served as President and CEO of Wave Life Sciences since 2013 and oversaw the company’s initial public offering in 2015. During his tenure as President and CEO, Dr. Bolno has grown Wave into a fully integrated clinical-stage genetic medicines company, overseen the development of the company’s proprietary stereopure oligonucleotide discovery and drug development platform, and built a broad pipeline of preclinical and clinical programs supported by scalable, in-house manufacturing capabilities.

In addition to Dr. Bolno’s current role at Wave, he is on the Board of Directors for SQZ Biotech and serves as Chairman of the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator (NATA) in the United Kingdom.

Prior to joining Wave, he was Vice President, Worldwide Business Development—Head of Asia BD and Investments, as well as Head of Global Neuroscience BD, at GlaxoSmithKline (GSK). He also served as a Director of Glaxo Wellcome Manufacturing, Pte Ltd. in Singapore. Dr. Bolno joined GSK as Vice President, Business Development for the Oncology Business Unit, where he helped establish GSK’s global oncology business and served as a member of the Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior to GSK, he served as Director of Research at Two River LLC, a healthcare private equity firm.

Dr. Bolno earned a medical degree from MCP-Hahnemann School of Medicine and an MBA from Drexel University. He was a general surgery resident and cardiothoracic surgery postdoctoral research fellow at Drexel University College of Medicine.

Advancing RNA medicines in genetic diseases, Paul Bolno, President & CEO, Wave Life Sciences

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 9, entitled, “Increased expression of musashi 1 on breast cancer cells has implication to understand dormancy and survival in bone marrow.”

Breast cancer (BC) stem cells (CSCs) resist treatment and can exist as dormant cells in tissues such as the bone marrow (BM). Years before clinical diagnosis, BC cells (BCCs) could migrate from the primary site where the BM niche cells facilitate dedifferentiation into CSCs. Additionally, dedifferentiation could occur by cell autonomous methods. 

In this new study, researchers George R. Nahas, Lauren S. Sherman, Garima Sinha, Markos H. El Far, Andrew Petryna, Steven M. Munoz, Kimberly A. Silverio, Maran Shaker, Pujan Neopane, Veronica Mariotti, and Pranela Rameshwar from Rutgers New Jersey Medical School studied the role of the RNA-binding protein, Musashi I (Msi 1). They also analyzed its relationship with the T-cell inhibitory molecule programmed death-ligand 1 (PD-L1) in CSCs.

“We validated the link between Msi 1 and PD-L1 in CSCs [cancer stem cells] based on significant reduction of CSCs following Msi 1 knockdown.”

PD-L1 is expressed on triple negative BC and other cancers. Therefore, PD-L1 is an immune checkpoint that is a target in immune therapy for cancers. Msi 1 can support BCC growth through stabilization of oncogenic transcripts and modulation of stem cell-related gene expression. The researchers reported on a role for Msi 1 to maintain CSCs. They found that it seemed to occur by the differentiation of CSCs to more matured BCCs. This correlated with increased transition from cycling quiescence and reduced expression of stem cell-linked genes. CSCs co-expressed Msi 1 and PD-L1. Msi 1 knockdown led to a significant decrease in CSCs with undetectable PD-L1. 

“This study has implications for Msi 1 as a therapeutic target, in combination with [an] immune checkpoint inhibitor. Such treatment could also prevent dedifferentiation of breast cancer to CSCs, and to reverse tumor dormancy. The proposed combined treatment might be appropriate for other solid tumors.”

DOI - https://doi.org/10.18632/aging.204620

Corresponding author - Pranela Rameshwar - rameshwa@njms.rutgers.edu

Sign up for free Altmetric alerts about this article - 
https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.204620

Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts

Keywords - aging, cancer stem cell, breast cancer, musashi 1, bone marrow, dormancy

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at https://www.Aging-US.com​​ and connect with us:

SoundCloud - https://soundcloud.com/Aging-Us
Facebook - https://www.facebook.com/AgingUS/
Twitter - https://twitter.com/AgingJrnl
Instagram - https://www.instagram.com/agingjrnl/
YouTube - https://www.youtube.com/@AgingJournal
LinkedIn - https://www.linkedin.com/company/aging/
Pinterest - https://www.pinterest.com/AgingUS/

Media Contact
18009220957
MEDIA@IMPACTJOURNALS.COM

Aging (Aging-US)

Musashi 1 in Breast Cancer: Implications for Dormancy and Survival in Bone Marrow

Dr. David Greene Arizona champions breakthrough stem cell therapy as a safer and more effective alternative to traditional surgeries for neck pain. With minimal downtime, this regenerative treatment harnesses the body's natural repair mechanisms, providing significant relief, improved mobility, and enhanced quality of life for patients. Dr. Greene and his team are dedicated to utilizing the transformative potential of stem cell therapy to deliver comprehensive care and lasting relief to individuals suffering from neck pain.

Dr. David Greene Arizona  Breakthrough Stem Cell Therapy For Neck Pain

In this captivating audio, listeners are invited to explore the groundbreaking realm of regenerative medicine, where the incredible potential of stem cell therapy takes center stage. Guided by the expertise and passion of a visionary leader, Dr. David Greene, founder and CEO of R3 Stem Cell and a former distinguished orthopedic surgeon from Arizona, this journey promises to be both enlightening and inspiring.

Exploring the Marvels of Stem Cell Therapy with Dr. David Greene Arizona

Dr. David Greene, a renowned expert in regenerative medicine, has been at the forefront of developing this groundbreaking technique to address a wide range of neurological and degenerative conditions. The procedure begins with the collection of stem cells from the patient's own body or from ethically sourced umbilical cord blood. These R3 stem cells possess remarkable regenerative properties, making them ideal for repairing damaged tissues and promoting natural healing processes.

Intrathecal Procedure For Stem Cell Therapy With R3   A Revolutionary Approach By Dr. David Greene

Dr. David Greene, an orthopedic surgeon with unmatched dedication, the center’s essence lies in its hands-on approach. Attendees aren't merely passive learners. They work on real patients, grasp real-world challenges, and find solutions alongside a supportive faculty. This ensures not just theoretical knowledge but a confidence to bring these skills into their practices swiftly.

R3 Medical Training Center In Scottsdale  A New Chapter In Healthcare Training With Dr. David Greene

Dr. David Greene Arizona pioneers hip care with R3 Stem Cell. Utilizing ultrasound for precise guidance, he ensures accurate injection delivery. This cutting-edge approach promotes faster recovery and enhanced results, revolutionizing contemporary orthopedic treatments

Redefining Hip Care  Ultrasound Guided Injections With R3 Stem Cell

Dr. David Greene Arizona  commitment to innovation is propelling the field of regenerative medicine to new heights. His relentless dedication to research has not only transformed the lives of countless patients but has also pushed the boundaries of what we thought possible in stem cell therapy. We’ll explore some of the most recent breakthroughs from his pioneering work.

Dr. David Greene’s Cutting - Edge Breakthroughs In Stem Cell Therapy

If you’re considering stepping into the transformative realm of regenerative medicine, there’s no better companion than R3 Stem Cell. Their track record speaks volumes, and countless testimonials echo the life-changing experiences many have had.

Navigating The New Frontiers Of Healing With R3 Stem Cell And Dr. David Greene (1)

Regenerative Medicine  Dr. David Greene's Mastery In Arizona's Stem Cell Therapy Landscape

r. David Greene, the founder and CEO of R3 Stem Cell, continues to be a beacon of innovation and patient-centered care in Arizona's medical landscape. His name has become almost synonymous with stem cell therapy, not only because of his former expertise as an orthopedic surgeon but also due to his deep commitment to revolutionizing regenerative medicine.

Dr. David Greene And The Evolution Of Stem Cell Therapy In Arizona

Dr Sanuri Liyanage joins ABC Regional Drive radio to explain her research team's discovery of a completely new type of cell known as 'Endomac progenitors'. The cells could have huge potential for wound healing and regenerating blood supply.

New stem cell discovery

The regenerative medicine therapy we offer at R3 Stem Cell helps people live healthier and pain-free lives. We staff our Centers of Excellence with experienced and compassionate providers dedicated to helping patients reach their health goals. Regenerative medicine therapies we offer include bone marrow, adipose, amniotic, PRP, and umbilical cord tissue. Exosomes and growth factors contained in these therapies can help the body heal itself.

Dr. David Greene, an orthopedic surgeon who is well-known for his regenerative medicine business, is highly qualified. David Greene, the CEO of R3 Stem Cell made it possible for tissue injuries to be treated without the need for surgery.

R3 Stem Cell International includes 45 clinics in 7 countries. These Centers of Excellence treat all types of conditions with safe, effective protocols by expert stem cell physicians.

Dr. David Greene Arizona residency-trained orthopaedic surgeon turned business entrepreneur. Founder of US Lead Network, revolutionizing healthcare internet marketing with AI-driven strategies. Author of two acclaimed books on Healthcare Internet Marketing. Recognized as a Top 20 Expert Author by Ezines.com, ranking #15 among 470,000 authors.

Aging-US is dedicated to advancing our understanding of the biological mechanisms that drive aging and the development of age-related diseases. Our mission is to serve as a platform for high-quality research that uncovers the cellular, molecular, and systemic processes underlying aging, and translates these insights into strategies to extend healthspan and delay the onset of chronic disease.

Read about the Aging (Aging-US) Scientific Integrity Process: https://aging-us.com/scientific-integrity

Biotech2050 Podcast is a think tank chronicling the disruptions changing the biotech industry over the next 50 years.

New tracks tagged #stemcell